Iksuda Therapeutics Closes $47 Million Financing Round
06/07/21, 8:32 AM
Location
newcastleMoney raised
$47 million
Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced it has completed a US $47 million (circa GB £34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. The funding will support the advancement of Iksuda’s lead ADC assets and expansion of its payload and conjugation platform technologies.
Company Info
Location
newcastle, washington, united states
Additional Info
Iksuda is an emerging biotechnology company focused on developing antibody-based therapies for the treatment of cancer as well as broader based therapeutics. Our main goal is to develop effective therapies to improve patients’ lives. Our mission is to enable improved clinical regimes through cre ...